Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a united states health maintenance organization

Pediatric Infectious Disease Journal

Volumn 29, Issue 7, 2010, Pages 613-617

  Klein, Nicola P ^a   Hansen, John ^a   Lewis, Edwin ^a   Lyon, Liisa ^a   Nguyen, Bessie ^a   Black, Steven ^b   Weston, Wayde M ^c   Wu, Sterling ^c   Li, Ping ^c   Howe, Barbara ^c   Friedland, Leonard R ^c  

^a KAISER PERMANENTE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

booster; diphtheria; pertussis; Tdap; tetanus; vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ALLERGIC REACTION; ANAPHYLACTOID PURPURA; ARTICLE; ASTHMA; AUTOIMMUNE THYROIDITIS; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIPHTHERIA; DRUG FATALITY; DRUG SAFETY; EXERCISE INDUCED ASTHMA; FEMALE; GEOGRAPHY; HASHIMOTO DISEASE; HEALTH CARE; HEALTH MAINTENANCE ORGANIZATION; HEMATOLOGIC DISEASE; HEPATITIS A; HEPATITIS B; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRITIS; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERTUSSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SEASON; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS; TONGUE SWELLING; UNITED STATES; UVEITIS; VACCINATION; CHEMICALLY INDUCED; HYPERSENSITIVITY; INCIDENCE;

ADOLESCENT; CALIFORNIA; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HEALTH MAINTENANCE ORGANIZATIONS; HEMATOLOGIC DISEASES; HUMANS; HYPERSENSITIVITY; INCIDENCE; MALE; NERVOUS SYSTEM DISEASES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 77954325361     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d581f9     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Pertussis\-United States 2001-2003. MMWR Morb Mortal Wkly Rep. 2005; 54, 1283-1286.
2. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med. 2006;19:603-611.
3. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422-1427.
4. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(suppl):S104-S108.
5. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39:1572-1580.
6. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23:985-989.
7. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Borde-tella pertussis to young infants. Pediatr Infect Dis J. 2007;26:293-299.
8. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34.
9. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37.
10. Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-4):1-51.
11. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348.
12. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129:695-701.
13. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37-41.
14. Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117:1084-1093.
15. Blatter MM, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid, and 3-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27:765-772.
16. Clopper C, Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
17. McClure DL, Glanz JM, Xu S, et al. Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine. 2008;26:3341-3345.
18. Lloyd JC, Haber P, Mootrey GT, et al. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. Vaccine. 2003;21:3746-3750.
19. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA. 1994;271:1602-1605.
20. Tuttle J, Chen RT, Rantala H, et al. The risk of Guillain-Barre syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health. 1997;87:2045-2048.
21. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27:4257-4262.